key: cord-0953606-1a5isoe6
authors: Juthani, Prerak V; Gupta, Akash; Borges, Kelly A; Price, Christina C; Lee, Alfred I; Won, Christine H; Chun, Hyung J
title: Hospitalisation among vaccine breakthrough COVID-19 infections
date: 2021-09-07
journal: Lancet Infect Dis
DOI: 10.1016/s1473-3099(21)00558-2
sha: 1872abca9c8b79def4c7ec6174efa250057eb351
doc_id: 953606
cord_uid: 1a5isoe6

nan

Emergency use authorisations granted by the US Food and Drug Administration for three SARS-CoV-2 vaccines represent an important milestone in the response to the COVID-19 pandemic. Data presented from the VIVALDI study by Shrotri and colleagues 1 and other phase 3 clinical trials 2-4 have shown robust vaccine efficacies (>85%) at preventing severe symptomatic disease. Although rare, emerging reports describe breakthrough SARS-CoV-2 infections in fully vaccinated individuals. 5 We describe the impact of vaccination on admission to hospital in patients with confirmed SARS-CoV-2 infection using real-world data collected by the Yale New Haven Health System. We did a systematic review of patients admitted to hospital with SARS-CoV-2 (confirmed by a positive PCR test at the time of admission) between March 23 and July 1, 2021. SARS-CoV-2 vaccination status was recorded, including the specific vaccine type (mRNA-1273 [elasomeran; Moderna], BNT162b2 [tozinameran; Pfizer-BioNTech], or Ad.26.COV2.S [Janssen]) and vaccination dates. Patients were considered fully vaccinated if the final dose (either second dose of BNT162b2 or mRNA-1273, or first dose of Ad.26.COV2.S) was administered at least 14 days before symptom onset or a positive PCR test for SARS-CoV-2. In total, we identified 969 patients who were admitted to a Yale New Haven Health System hospital with a confirmed positive PCR test for SARS-CoV-2. Severity of COVID-19 infection was determined on the basis of established guidelines. 6 172 (18%) of 969 patients had received at least one dose of a COVID-19 vaccine at the time of admission to hospital. Among these patients, 103 had received a partial vaccine course (one dose of BNT162b2 or mRNA-1273), 15 had received a complete course (two doses of BNT162b2 or mRNA-1273 or one dose of Ad.26.COV2.S within 14 days before symptom onset or a positive PCR test), and 54 were fully vaccinated (appendix pp 1-2). Patients deemed to have a breakthrough SARS-CoV-2 infection-ie, the 54 patients who were fully vaccinatedwere evaluated for illness severity. Among this cohort, we found that 25 (46%) patients were asymptomatic (admitted to hospital for a non-COVID-19-related diagnosis but with an incidental positive PCR test for SARS-CoV-2), four (7%) had mild disease, 11 (20%) had moderate disease, and 14 (26%) had severe or critical illness. Among those with severe or critical illness, the median age was 80·5 years (IQR 76·5-85·0); four of 14 patients required intensive care, one required mechanical ventilation, and three died. Pre-existing comorbidities in the 14 patients with severe or critical illness included overweight (body-mass index >25 kg/m²; n=9), cardiovascular disease (n=12), lung disease (n=7), malignancy (n=4), type 2 diabetes (n=7), and use of an immunosuppressive agent (n=4; appendix pp 3). 13 of 14 patients had received BNT162b2 (appendix p 1-2).

Vaccination for SARS-CoV-2 is highly effective against infection with SARS-CoV-2 or hospitalisation with COVID-19. In our real-world assessment of patients admitted to hospital with a positive SARS-CoV-2 PCR test, we found that nearly a fifth of patients had received at least one dose of the vaccine, and we observed that many patients had not completed the full vaccine course. The finding that more than a quarter of fully vaccinated patients admitted to hospital with SARS-CoV-2 were severely or critically ill with COVID-19 could be reflective of numerous factors, including the emergence of SARS-CoV-2 variants that might confer decreased vaccine effectiveness and an ineffective immune response mounted against vaccines among those with comorbidities-eg, older age, overweight, and use of immunosuppressive agents. Although the incidence of severe or critical COVID-19 illness remains low in those who are fully vaccinated, we observed a higher number of patients with severe or critical illness in those who received the BNT162b2 vaccine than in those who received mRNA-1273 or Ad. 26 

We declare no competing interests. PVJ, AG, and KAB contributed equally to this Comment. The Yale University institutional review board approved the study (2000027792) and waived the need for informed consent

Section of Pulmonary

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine

SARS-CoV-2 infection after vaccination in health care workers in California

Clinical spectrum of SARS-CoV-2 infection

COVID-19 vaccine distribution in Connecticut